Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-11
2011-12-27
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S275000, C514S313000, C514S343000, C544S331000, C544S332000, C544S363000, C546S162000, C546S278700
Reexamination Certificate
active
08084454
ABSTRACT:
Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
REFERENCES:
patent: 5935966 (1999-08-01), Suto et al.
patent: 6291447 (2001-09-01), Andersen et al.
patent: 6476061 (2002-11-01), Rheinheimer et al.
patent: 2004/0198727 (2004-10-01), Kawabe et al.
patent: 1 218 494 (2005-04-01), None
patent: 07 224032 (1995-08-01), None
patent: 97/09325 (1997-03-01), None
patent: 00/30445 (2000-06-01), None
patent: 01/62087 (2001-08-01), None
patent: 2005/024755 (2005-03-01), None
patent: 2006/086255 (2006-08-01), None
patent: 2007/053765 (2007-05-01), None
patent: 2008/110891 (2008-09-01), None
Hartwell, Leland, Defects in a Cell Cycle Checkpoint May be Responsible for the Genomic Instability of Cancer Cells, Cell, 1992, 71, 543-546.
Kawabe, Takume, G2Checkpoint Abrogators as Anticancer Drugs, Mol.Cancer Ther., 2004, 3(4), 513-519.
Mailer, James L., Mitotic Control, Current Opinion in Cell Biology, 1991, 3, 369-275.
Piers, Edward, et al., Improved Synthesis of Isogranulatimide, a G2 Checkpoint Inhibitor, Syntheses of Didemnimide C, Isodidemnimide A, Neodidemnimide A, 17-Methylgranulatimide, and dlsogranulatimides A-C, J. Org. Chem., 2000, 65, 530-535.
Sha, Shi-Ken, et al., Cell Cycle Phenotype-Based Optimization of G2-Abrogating Peptides Yields CBP501 With a Unique Mechanism of Action at the G2Checkpoint, Mol. Cancer Ther., 2007, 6(1), 147-53.
CAS Registry entry No. 910441-85-9; entry date Oct. 15, 2006.
CAS Registry entry No. 138949-46-9; entry date Feb. 14, 1992.
CAS Registry entry No. 138949-42-5; entry date Feb. 14, 1992.
CAS Registry entry No. 138949-41-4; entry date Feb. 14, 1992.
CAS Registry entry No. 138949-40-3; entry date Feb. 14, 1992.
CAS Registry entry No. 138949-26-5; entry date Feb. 14, 1992.
CAS Registry entry No. 144173-20-6; entry date Oct. 28, 1992.
CAS Registry entry No. 84686-99-7; entry date Nov. 16, 1984.
CAS Registry entry No. 74180-27-1; entry date Nov. 16, 1984.
CAS Registry entry No. 731832-52-3; entry date Aug. 24, 2004.
CAS Registry entry No. 732257-97-5; entry date Aug. 24, 2004.
Palanski, M.S., et al., Novel Inhibitors of AP-1 and NF-KappaB Mediated Gene Expression: Structure-Activity Relationship Studies of Ethyl 4-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimi dine-5-carboxylate,Bioorganic&Medicinal Chemistry Letters, Pergamon, Elsevier Science, 2000, 10(15):1645-1648, XP004213214.
Palanski, M.S., et al., The Design and Synthesis of Novel Orally Active Inhibitors of AP-1 and NF-kB Mediated Transcriptional Activation. SAR of in vitro and in vivo Studies,Bioorganic&Medicinal Chemistry Letters, 2003, 13:4077-4080, XP002518652.
Database Beilstein Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002518653, Database accession No. BRN:1477866 abstract & Chemical and Pharmaceutical Bulletin, 1967, 15:1101-1104, XP002518653.
Singapore Patent Application No. 200906750-5, Intellectual Property Office of Singapore, Search and Examination Report issued Apr. 6, 2011.
Hasegawa Yoko
Ishigaki Machiyo
Kawabe Takumi
Sato Takuji
Yamamoto Sayaka
Canbas Co., Ltd.
Pillsbury Winthrop Shaw & Pittman LLP
Sackey Ebenezer O
Wilson James O
LandOfFree
Compounds with anti-cancer activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds with anti-cancer activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds with anti-cancer activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271317